Glaxo Smith Kline results, Fiscal year 2025
Net profit, assets, equity and cash flow for Fiscal year 2025, against the same period a year earlier, from the published financial statements.
Net profit213 millionEGP · +22.6% vs the same period a year earlier
Total assets4.5 billionEGP · +23.2% vs the same period a year earlier
Shareholders' equity2.22 billionEGP · +11.1% vs the same period a year earlier
Operating cash flow241 millionEGP · +159.6% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Fiscal year 2025 was about 213 million EGP, up +22.6% from 174 million EGP in Fiscal year 2024.
- Total assets at the end of Fiscal year 2025 were about 4.5 billion EGP, and shareholders' equity about 2.22 billion EGP.
- Operating cash flow for Fiscal year 2025 was positive at 241 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2024Change
Net profit213 million174 million+22.6%
Gross profit904 million1.14 billion−21.0%
Total assets4.5 billion3.65 billion+23.2%
Total liabilities2.28 billion1.66 billion+37.8%
Shareholders' equity2.22 billion2 billion+11.1%
Total liabilities and equity4.5 billion3.65 billion+23.2%
Operating cash flow241 million-404 million+159.6%
Investing cash flow115 million-226 million+151.0%
Financing cash flow48 million-124 million+138.8%
Net change in cash404 million-754 million+153.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy